JP7543290B2 - 抗trem2抗体及びその使用方法 - Google Patents
抗trem2抗体及びその使用方法 Download PDFInfo
- Publication number
- JP7543290B2 JP7543290B2 JP2021548668A JP2021548668A JP7543290B2 JP 7543290 B2 JP7543290 B2 JP 7543290B2 JP 2021548668 A JP2021548668 A JP 2021548668A JP 2021548668 A JP2021548668 A JP 2021548668A JP 7543290 B2 JP7543290 B2 JP 7543290B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- cdr
- trem2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024139367A JP7842822B2 (ja) | 2019-02-20 | 2024-08-21 | 抗trem2抗体及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| US62/808,141 | 2019-02-20 | ||
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139367A Division JP7842822B2 (ja) | 2019-02-20 | 2024-08-21 | 抗trem2抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520868A JP2022520868A (ja) | 2022-04-01 |
| JP2022520868A5 JP2022520868A5 (cg-RX-API-DMAC7.html) | 2023-02-27 |
| JP7543290B2 true JP7543290B2 (ja) | 2024-09-02 |
Family
ID=69844940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548668A Active JP7543290B2 (ja) | 2019-02-20 | 2020-02-20 | 抗trem2抗体及びその使用方法 |
| JP2024139367A Active JP7842822B2 (ja) | 2019-02-20 | 2024-08-21 | 抗trem2抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024139367A Active JP7842822B2 (ja) | 2019-02-20 | 2024-08-21 | 抗trem2抗体及びその使用方法 |
Country Status (21)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3902836B1 (en) * | 2018-12-18 | 2026-03-25 | Boehringer Ingelheim IO Canada Inc. | Flt3 agonist antibodies and uses thereof |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| EP4232087A4 (en) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS |
| WO2022241082A1 (en) * | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
| MX2024010324A (es) | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| EP4499695A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| JP2026505005A (ja) | 2023-01-30 | 2026-02-10 | イーエスアーエル バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経変性障害を治療するためのヒト抗trem2抗体 |
| AU2024320793A1 (en) | 2023-08-09 | 2026-03-12 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| KR20260113065A (ko) * | 2023-11-15 | 2026-07-21 | 머크 샤프 앤드 돔 엘엘씨 | 인간 넥틴-4 결합제 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017523814A (ja) | 2014-08-08 | 2017-08-24 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| WO2018195506A1 (en) | 2017-04-21 | 2018-10-25 | Amgen Inc. | Trem2 antigen binding proteins and uses thereof |
| JP2018537956A (ja) | 2015-10-06 | 2018-12-27 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| WO2019028292A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| RU2011133071A (ru) | 2009-01-06 | 2013-02-20 | Нестек С.А. | Переработка макронутриентов |
| NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| WO2012176779A1 (ja) * | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | 抗erbB3抗体 |
| CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| EP3041865A2 (en) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| JP6996979B2 (ja) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 三量体tnfファミリーリガンドを含む抗原結合分子 |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) | Trem2切断モジュレーター及びその使用 |
| CN118271442A (zh) | 2016-12-23 | 2024-07-02 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| US20190367623A1 (en) | 2017-01-17 | 2019-12-05 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| CA3053379A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| CA3053381A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019079529A1 (en) | 2017-10-17 | 2019-04-25 | The Translational Genomics Research Institute | TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| BR112020013921A2 (pt) | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| CA3109763A1 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| EP3840781A1 (en) | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
| SG11202102162RA (en) | 2018-09-11 | 2021-04-29 | Univ Washington | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 trem2 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CN113302206A (zh) | 2018-11-26 | 2021-08-24 | 戴纳立制药公司 | 治疗脂质代谢失调的方法 |
| EP3894864A2 (en) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| CA3122725A1 (en) | 2018-12-10 | 2020-06-18 | Mor Research Applications | Trem2 antibodies and uses thereof |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| CA3170338A1 (en) | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
-
2020
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko not_active Ceased
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
-
2021
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP7842822B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017523814A (ja) | 2014-08-08 | 2017-08-24 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| JP2018537956A (ja) | 2015-10-06 | 2018-12-27 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| WO2018195506A1 (en) | 2017-04-21 | 2018-10-25 | Amgen Inc. | Trem2 antigen binding proteins and uses thereof |
| WO2019028292A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113614110A (zh) | 2021-11-05 |
| SG11202108734VA (en) | 2021-09-29 |
| EP3927743A1 (en) | 2021-12-29 |
| PE20211979A1 (es) | 2021-10-05 |
| US20220073609A1 (en) | 2022-03-10 |
| JP2024164116A (ja) | 2024-11-26 |
| TWI879756B (zh) | 2025-04-11 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| CO2021012230A2 (es) | 2021-09-30 |
| WO2020172457A1 (en) | 2020-08-27 |
| CN113614110B (zh) | 2025-03-25 |
| PH12021552002A1 (en) | 2022-09-19 |
| WO2020172450A1 (en) | 2020-08-27 |
| TW202045543A (zh) | 2020-12-16 |
| AU2020226754A1 (en) | 2021-09-16 |
| IL285651A (en) | 2021-09-30 |
| CA3130086A1 (en) | 2020-08-27 |
| JP2022520868A (ja) | 2022-04-01 |
| EA202192294A1 (ru) | 2021-12-24 |
| US12240902B2 (en) | 2025-03-04 |
| ECSP21069105A (es) | 2021-11-18 |
| MX2021009722A (es) | 2021-09-14 |
| JP7842822B2 (ja) | 2026-04-08 |
| KR20210135518A (ko) | 2021-11-15 |
| AR118144A1 (es) | 2021-09-22 |
| MA55025A (fr) | 2021-12-29 |
| US20220119522A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7842822B2 (ja) | 抗trem2抗体及びその使用方法 | |
| US11124567B2 (en) | Anti-TREM2 antibodies and methods of use thereof | |
| TWI890727B (zh) | 抗trem2 抗體及其使用方法 | |
| JP7403441B2 (ja) | 抗trem2抗体及びその使用方法 | |
| TW201827466A (zh) | 抗-tau抗體及使用方法 | |
| CN104736185A (zh) | 治疗Tau病变的方法 | |
| EA049305B1 (ru) | Антитела к trem2 и способы их применения | |
| HK40063035A (en) | Anti-trem2 antibodies and methods of use thereof | |
| HK40082564A (en) | Anti-trem2 antibodies and methods of use thereof | |
| US20250215077A1 (en) | Monovalent anti-trem2 binding molecules and methods of use thereof | |
| TW202515915A (zh) | 抗pilra抗體、其用途以及相關方法及試劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230216 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20231012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240401 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240723 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240821 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7543290 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |